Australian patients support PBS spending, survey shows

25 November 2013

A survey released today has revealed that Australians overwhelming support the government’s Pharmaceutical Benefits Scheme (PBS).

A Galaxy Research poll sponsored by research firm Ethical Strategies and trade journal PharmaDispatch looked at the attitudes and experiences of Australians receiving prescription medicines for chronic illnesses. It questioned 1,910 adults and 1,000 patients taking prescription drugs on a daily basis.

It found that Australians are hopeful and expectant that pharmaceutical R&D will lead to improved treatments, and delayed access to new medicines is a genuine concern. It added that the PBS is seen as a good use of taxes, especially among concessional card holders and those taking four or more medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >